Neutrophils in Respiratory Syncytial Virus Infection: From Harmful Effects to Therapeutic Opportunities Publisher Pubmed



Tahamtan A^{1, 2} ; Besteman S^{3, 4} ; Samadizadeh S^{1, 2} ; Rastegar M² ; Bont L³ ; Salimi V⁵ Show Affiliations
Source: British Journal of Pharmacology Published:2021

Abstract

Respiratory syncytial virus (RSV) is an important infectious agent in infants and young children. In most cases, RSV infection only causes mild disease, but in some, it requires invasive ventilation. Although antiviral drugs are obvious candidates to treat viral illness, and some have shown antiviral effects in humans, antivirals such as GS-5806, ALX-0171 and ALS-8176 have not yet met their expectations. Since the inappropriate or dysregulated immune response against RSV leads to harmful immune pathology, a robust immune cascade is probably underway by the time patients reach the hospital. RSV infection is associated with a strong neutrophil influx into the airway. It not clear if these cells contribute to antiviral defence or to lung pathology. This article discusses the protective and harmful roles of neutrophils during RSV infection and provides an overview of mechanisms by which neutrophil function could be targeted to prevent tissue injury and preserve homeostasis. © 2020 The British Pharmacological Society